### Overview

### Genital immunology, the microbiota and HIV transmission

#### Dr. Rupert Kaul University of Toronto

#### · Genital mucosal inflammation - Association with HIV acquisition

- · Co-infections and genital microbiome have important mucosal impacts
  - May enhance mucosal homing of susceptible T cells
  - And/or induce cytokines that alter barrier function
- Important effects on HIV shedding in an HIV+ person - Not covered today

## **Mucosal HIV infection**



## Mucosal immune studies



- · Sigmoid colon studies in Toronto
- Foreskin studies in Rakai, Uganda
- Cervical studies in Toronto, Nairobi

### Mucosal CD4+ cells appear more HIV susceptible



- Cervix, other mucosal sites enriched for effector memory cells
- Much higher levels of immune activation
- HIV co-receptor & integrin expression

#### Enhanced virus entry in mucosal T cells



- Virus entry higher in
- cervix
- But blood, cervix
- correlated
- Enhanced in CD69+ and CCR5+ cells
- Also α4β7+, α4β1+ subsets

Joag V. Muc Immunol, 2015.

#### Mucosal inflammation and HIV risk

- Cervical α-defensins, cathelicidins associated with HIV acquisition in Kenyan women

   despite *in vitro* antiviral effects
- Foreskin  $\alpha\text{-defensins}$  associated with HIV acquisition in Ugandan men
- Cervical inflammatory cytokines associated with HIV acquisition in South African women

Levinson. AIDS, 2009. Hirbod. PLoS Path, 2014. Passmore. Clin ID, 2015.

#### Foreskin cytokines and HIV acquisition

	Cytokine Prevalence				Headlysted Odds Batis	Adjusted Odds Batia
	Controls		Seroconverters		(95% CI)	/05% CT)
	n=120	95	n=60	96	(35 % 61)	(35% 61)
IL-8	63	52.5	44	73.3	2.52 (1.28, 4.99)	2.58 (1.04, 6.40)
MIG	23	19.7	22	36.7	2.49 (1.23, 5.03)	3.05 (1.15, 8.06)
GM-CSF	5	4.2	7	11.7	3.02 (0.92, 9.91)	
MCP-1	6	5.0	6	10.0	2.10 (0.65, 6.79)	
MIP3a	4	3.3	5	8.3	2.61 (0.68, 10.06)	
IL-1a	4	3.3	3	5.0	1.53 (0.33, 7.16)	
RANTES	3	2.5	2	3.3	1.35 (0.22, 8.30)	

\*Conditional logistic regression (matched by visit), controlling for age, STIs (syphilis and HSV-2 and all variables associated with either seroconversion or IL-8 or MIG detectability (occupation, marital status, having multiple sexpartmers, condom use, consumption of alcohol).

- Foreskin swabs collected during Rakai clinical trial of MC – 60 men who acquired HIV and 120 uninfected controls
- Levels of many cytokines low; more IL-8 (aOR 2.6) and MIG (aOR 3.1) among men who subsequently acquired HIV

Prodger J, CROI 2014.

# How is genital inflammation increasing susceptibility?

- N=96 HIV neg Kenyan women
- Inflammation if ≥3/7 proinflammatory cytokines in upper quartile (n=28)
- Cytobrush (cell studies) and CVL (proteomics)



Arnold K and Burgener A. Muc Immunol, 2015.

# Mucosal effects of genital inflammation: proteomic analysis

- CD4+ cell numbers doubled in the context of inflammation
- Proteome also altered: some parameters increased, others lower



Arnold K et al. Muc Immunol, 2015.

#### Proteomic associations of FGT inflammation



- Up-regulation of neutrophil proteases, cell motility, actin cytoskeleton
- **Down**-regulation of antiproteases, keratinization, epithelial differentiation

# Immune associations of clinical conditions that enhance HIV risk

- Several clinical conditions consistently associated with increased HIV acquisition risk
- 1. Asymptomatic HSV-2 infection (OR=2.8-3.4)
- Bacterial vaginosis, ie: disruption in 'normal' vaginal microbiota (OR=1.6)

Glynn. AIDS, 2009. Atashili. AIDS, 2008.

#### Asymptomatic HSV2 and genital immunology



#### ACKNOWLEDGEMENTS:

Kaul lab: Sanja Huibner, <u>Vineet Joag</u>, Connie Kim, Ronald Galiwango, Sergey Yegorov, Rodney Rousseau, <u>Jessica Prodger, Brett Shannon</u>, Kamnoosh Shahabi, Avid Mohammedi, Yoojin Choi University of Toronto: Mario Ostrowski, Robert Remis, Kelly MacDonald, Mark Yudin, Robert Reinhard, Ron Rosenes

MHIWH, Toronto: Lisungu Chieza, <u>Wangari Tharao</u>, Jamie Pavanel-Thomas Maple Leaf Medical Clinic: Colin Kovacs, Mona Loutfy, Roberta Halpenny, Erika Benko Independent Found Contract Control (Lip), Horis Colory, Nobertal Engenny, Editor Defindo University of Nairobi: <u>Toshwa Kimani</u>) Walter Jaoko, Tony Karrin, Person Fulla, Makobu Kimani, Jessie Kwatampora Univ. of Manitoba: Frank Plummer, Blake Ball, Keith Fowke, <u>Adam Burgener</u>, Kenzie Birse

Karolinska Institute: Taha Hirbod, Kristina Broliden, Pauline Levinson Rakai HSC, Uganda: Nelson Sewankambo, David Serwadda, Fred Nalugoda, Godfrey Kigosi Johns Hopkins University: Ron Gray, Maria Wawer, Aaron Tobian

University of Maryland: Jacques Ravel, Pawel Bayer IAVI, Uganda: Leslie Neilson, Noah Kiwanuka, Aloysius Ssemaganda NIH: James Arthos, Claudia Cicala, Tae-Wook Chun

TGen Institute, Arizona: Lance Price, <u>Cindy Liu</u> CAPRISA, RSA: Salim and Quarraisha Abdool Karim, <u>Lyle McKinnon</u>, Jo-Ann Passmore, Lindi Masson, Lenine Liebenberg MIT: Kelly Arnold, Douglas Lauffenburger

FUNDING: <u>Canadian Institutes of Health Research</u> Ontario HIV Treatment Network NIH, Gates Foundation



#### Summary

- Genital mucosal inflammation
  - (i) recruits HIV susceptible target cells, and (ii) alters epithelial integrity
  - possibly mediated via different effector cytokines
- Often these things happen together, but not necessarily
  - HSV2: increased HIV target cell numbers without inflammatory cytokines
  - Dysbiosis: increased inflammatory cytokines without cell number/subset alterations
- Possible implications for populations where both are common, esp. ACB women